Common neurodegenerative pathways in obesity, diabetes, and Alzheimer's disease

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1863, Issue 5, 2017, Pages 1037-1045

  Pugazhenthi, Subbiah ^a,b   Qin, Limei ^a   Reddy, P Hemachandra ^c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Advanced glycation end products; Alzheimer's disease; Diabetes; Inflammation; Mitochondria; Obesity; Oxidative stress

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR;

ALZHEIMER DISEASE; ANIMAL; BLOOD BRAIN BARRIER; BRAIN; COMPLICATION; DIABETES MELLITUS; DIABETIC COMPLICATION; HUMAN; INFLAMMATION; METABOLISM; MITOCHONDRION; OBESITY; OXIDATIVE STRESS; PATHOLOGY;

ALZHEIMER DISEASE; ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; DIABETES COMPLICATIONS; DIABETES MELLITUS; GLYCATION END PRODUCTS, ADVANCED; HUMANS; INFLAMMATION; MITOCHONDRIA; OBESITY; OXIDATIVE STRESS; RECEPTOR FOR ADVANCED GLYCATION END PRODUCTS;

EID: 84971597460     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2016.04.017     Document Type: Article

References (138)

1. [1] Wild, S., Roglic, G., Green, A., Sicree, R., King, H., Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27 (2004), 1047–1053.
2. [2] Kelly, T., Yang, W., Chen, C.S., Reynolds, K., He, J., Global burden of obesity in 2005 and projections to 2030. Int. J. Obes. 32 (2008), 1431–1437.
3. [3] Whitmer, R.A., Gustafson, D.R., Barrett-Connor, E., Haan, M.N., Gunderson, E.P., Yaffe, K., Central obesity and increased risk of dementia more than three decades later. Neurology 71 (2008), 1057–1064.
4. [4] Jagust, W., Harvey, D., Mungas, D., Haan, M., Central obesity and the aging brain. Arch. Neurol. 62 (2005), 1545–1548.
5. [5] Whitmer, R.A., Gunderson, E.P., Barrett-Connor, E., Quesenberry, C.P. Jr., Yaffe, K., Obesity in middle age and future risk of dementia: a 27 year longitudinal population based study. BMJ, 330, 2005, 1360.
6. [6] Hassing, L.B., Dahl, A.K., Thorvaldsson, V., Berg, S., Gatz, M., Pedersen, N.L., Johansson, B., Overweight in midlife and risk of dementia: a 40-year follow-up study. Int. J. Obes. 33 (2009), 893–898.
7. [7] Hassing, L.B., Dahl, A.K., Pedersen, N.L., Johansson, B., Overweight in midlife is related to lower cognitive function 30 years later: a prospective study with longitudinal assessments. Dement. Geriatr. Cogn. Disord. 29 (2010), 543–552.
8. [8] Anstey, K.J., Cherbuin, N., Budge, M., Young, J., Body mass index in midlife and late-life as a risk factor for dementia: a meta-analysis of prospective studies. Obes. Rev. 12 (2011), e426–e437.
9. [9] Fitzpatrick, A.L., Kuller, L.H., Lopez, O.L., Diehr, P., O'Meara, E.S., Longstreth, W.T. Jr., Luchsinger, J.A., Midlife and late-life obesity and the risk of dementia: cardiovascular health study. Arch. Neurol. 66 (2009), 336–342.
10. [10] Xu, W.L., Atti, A.R., Gatz, M., Pedersen, N.L., Johansson, B., Fratiglioni, L., Midlife overweight and obesity increase late-life dementia risk: a population-based twin study. Neurology 76 (2011), 1568–1574.
11. [11] Wotton, C.J., Goldacre, M.J., Age at obesity and association with subsequent dementia: record linkage study. Postgrad. Med. J. 90 (2014), 547–551.
12. [12] Nepal, B., Brown, L.J., Anstey, K.J., Rising midlife obesity will worsen future prevalence of dementia. PLoS One, 9, 2014, e99305.
13. [13] Qizilbash, N., Gregson, J., Johnson, M.E., Pearce, N., Douglas, I., Wing, K., Evans, S.J., Pocock, S.J., BMI and risk of dementia in two million people over two decades: a retrospective cohort study. Lancet Diabetes Endocrinol. 3 (2015), 431–436.
14. [14] Lee, H.M., Kim, J.J., Kim, H.J., Shong, M., Ku, B.J., Jo, E.K., Upregulated NLRP3 inflammasome activation in patients with type 2 diabetes. Diabetes 62 (2013), 194–204.
15. [15] Snodgrass, R.G., Huang, S., Choi, I.W., Rutledge, J.C., Hwang, D.H., Inflammasome-mediated secretion of IL-1beta in human monocytes through TLR2 activation; modulation by dietary fatty acids. J. Immunol. 191 (2013), 4337–4347.
16. [16] Purdon, D., Arai, T., Rapoport, S., No evidence for direct incorporation of esterified palmitic acid from plasma into brain lipids of awake adult rat. J. Lipid Res. 38 (1997), 526–530.
17. [17] Karmi, A., Iozzo, P., Viljanen, A., Hirvonen, J., Fielding, B.A., Virtanen, K., Oikonen, V., Kemppainen, J., Viljanen, T., Guiducci, L., Haaparanta-Solin, M., Nagren, K., Solin, O., Nuutila, P., Increased brain fatty acid uptake in metabolic syndrome. Diabetes 59 (2010), 2171–2177.
18. [18] Cole, G.M., Ma, Q.L., Frautschy, S.A., Dietary fatty acids and the aging brain. Nutr. Rev. 68:Suppl. 2 (2010), S102–S111.
19. [19] Gupta, S., Knight, A.G., Keller, J.N., Bruce-Keller, A.J., Saturated long-chain fatty acids activate inflammatory signaling in astrocytes. J. Neurochem. 120 (2012), 1060–1071.
20. [20] Milanski, M., Degasperi, G., Coope, A., Morari, J., Denis, R., Cintra, D.E., Tsukumo, D.M., Anhe, G., Amaral, M.E., Takahashi, H.K., Curi, R., Oliveira, H.C., Carvalheira, J.B., Bordin, S., Saad, M.J., Velloso, L.A., Saturated fatty acids produce an inflammatory response predominantly through the activation of TLR4 signaling in hypothalamus: implications for the pathogenesis of obesity. J. Neurosci. 29 (2009), 359–370.
21. [21] Takalo, M., Haapasalo, A., Martiskainen, H., Kurkinen, K.M., Koivisto, H., Miettinen, P., Khandelwal, V.K., Kemppainen, S., Kaminska, D., Makinen, P., Leinonen, V., Pihlajamaki, J., Soininen, H., Laakso, M., Tanila, H., Hiltunen, M., High-fat diet increases tau expression in the brain of T2DM and AD mice independently of peripheral metabolic status. J. Nutr. Biochem. 25 (2014), 634–641.
22. [22] Wilson, D.M., Binder, L.I., Free fatty acids stimulate the polymerization of tau and amyloid beta peptides. In vitro evidence for a common effector of pathogenesis in Alzheimer's disease. Am. J. Pathol. 150 (1997), 2181–2195.
23. [23] Cukierman-Yaffe, T., Gerstein, H.C., Williamson, J.D., Lazar, R.M., Lovato, L., Miller, M.E., Coker, L.H., Murray, A., Sullivan, M.D., Marcovina, S.M., Launer, L.J., Relationship between baseline glycemic control and cognitive function in individuals with type 2 diabetes and other cardiovascular risk factors: the action to control cardiovascular risk in diabetes-memory in diabetes (ACCORD-MIND) trial. Diabetes Care 32 (2009), 221–226.
24. [24] Ohara, T., Doi, Y., Ninomiya, T., Hirakawa, Y., Hata, J., Iwaki, T., Kanba, S., Kiyohara, Y., Glucose tolerance status and risk of dementia in the community: the Hisayama study. Neurology 77 (2011), 1126–1134.
25. [25] Ding, J., Strachan, M.W., Reynolds, R.M., Frier, B.M., Deary, I.J., Fowkes, F.G., Lee, A.J., McKnight, J., Halpin, P., Swa, K., Price, J.F., Diabetic retinopathy and cognitive decline in older people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. Diabetes 59 (2010), 2883–2889.
26. [26] Crane, P.K., Walker, R., Hubbard, R.A., Li, G., Nathan, D.M., Zheng, H., Haneuse, S., Craft, S., Montine, T.J., Kahn, S.E., McCormick, W., McCurry, S.M., Bowen, J.D., Larson, E.B., Glucose levels and risk of dementia. N. Engl. J. Med. 369 (2013), 540–548.
27. [27] Spauwen, P.J., Kohler, S., Verhey, F.R., Stehouwer, C.D., van Boxtel, M.P., Effects of type 2 diabetes on 12-year cognitive change: results from the Maastricht Aging Study. Diabetes Care 36 (2013), 1554–1561.
28. [28] Cukierman, T., Gerstein, H.C., Williamson, J.D., Cognitive decline and dementia in diabetes—systematic overview of prospective observational studies. Diabetologia 48 (2005), 2460–2469.
29. [29] Yaffe, K., Blackwell, T., Whitmer, R.A., Krueger, K., Barrett Connor, E., Glycosylated hemoglobin level and development of mild cognitive impairment or dementia in older women. J. Nutr. Health Aging 10 (2006), 293–295.
30. [30] Sommerfield, A.J., Deary, I.J., Frier, B.M., Acute hyperglycemia alters mood state and impairs cognitive performance in people with type 2 diabetes. Diabetes Care 27 (2004), 2335–2340.
31. [31] Ravona-Springer, R., Moshier, E., Schmeidler, J., Godbold, J., Akrivos, J., Rapp, M., Grossman, H.T., Wysocki, M., Silverman, J.M., Haroutunian, V., Beeri, M.S., Changes in glycemic control are associated with changes in cognition in non-diabetic elderly. J. Alzheimers Dis. 30 (2012), 299–309.
32. [32] Ravona-Springer, R., Heymann, A., Schmeidler, J., Moshier, E., Godbold, J., Sano, M., Leroith, D., Johnson, S., Preiss, R., Koifman, K., Hoffman, H., Silverman, J.M., Beeri, M.S., Trajectories in glycemic control over time are associated with cognitive performance in elderly subjects with type 2 diabetes. PLoS One, 9, 2014, e97384.
33. [33] Kirkman, M.S., Briscoe, V.J., Clark, N., Florez, H., Haas, L.B., Halter, J.B., Huang, E.S., Korytkowski, M.T., Munshi, M.N., Odegard, P.S., Pratley, R.E., Swift, C.S., Diabetes in older adults: a consensus report. J. Am. Geriatr. Soc. 60 (2012), 2342–2356.
34. [34] Baker, L.D., Cross, D.J., Minoshima, S., Belongia, D., Watson, G.S., Craft, S., Insulin resistance and Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early type 2 diabetes. Arch. Neurol. 68 (2011), 51–57.
35. [35] Strachan, M.W., Reynolds, R.M., Marioni, R.E., Price, J.F., Cognitive function, dementia and type 2 diabetes mellitus in the elderly. Nat. Rev. Endocrinol. 7 (2011), 108–114.
36. [36] Wang, J., Gong, B., Zhao, W., Tang, C., Varghese, M., Nguyen, T., Bi, W., Bilski, A., Begum, S., Vempati, P., Knable, L., Ho, L., Pasinetti, G.M., Epigenetic mechanisms linking diabetes and synaptic impairments. Diabetes 63 (2014), 645–654.
37. [37] Qiu, W.Q., Folstein, M.F., Insulin, insulin-degrading enzyme and amyloid-beta peptide in Alzheimer's disease: review and hypothesis. Neurobiol. Aging 27 (2006), 190–198.
38. [38] Haque, R., Nazir, A., Insulin-degrading enzyme: a link between Alzheimer's and type 2 diabetes mellitus. CNS Neurol. Disord. Drug Targets 13 (2014), 259–264.
39. [39] Akter, K., Lanza, E.A., Martin, S.A., Myronyuk, N., Rua, M., Raffa, R.B., Diabetes mellitus and Alzheimer's disease: shared pathology and treatment?. Br. J. Clin. Pharmacol. 71 (2011), 365–376.
40. [40] Kroner, Z., The relationship between Alzheimer's disease and diabetes: type 3 diabetes?. Altern. Med. Rev. 14 (2009), 373–379.
41. [41] Ramos-Rodriguez, J.J., Molina-Gil, S., Ortiz-Barajas, O., Jimenez-Palomares, M., Perdomo, G., Cozar-Castellano, I., Lechuga-Sancho, A.M., Garcia-Alloza, M., Central proliferation and neurogenesis is impaired in type 2 diabetes and prediabetes animal models. PLoS One, 9, 2014, e89229.
42. [42] Gage, F.H., Mammalian neural stem cells. Science 287 (2000), 1433–1438.
43. [43] Lang, B.T., Yan, Y., Dempsey, R.J., Vemuganti, R., Impaired neurogenesis in adult type-2 diabetic rats. Brain Res. 1258 (2009), 25–33.
44. [44] Beauquis, J., Saravia, F., Coulaud, J., Roig, P., Dardenne, M., Homo-Delarche, F., De Nicola, A., Prominently decreased hippocampal neurogenesis in a spontaneous model of type 1 diabetes, the nonobese diabetic mouse. Exp. Neurol. 210 (2008), 359–367.
45. [45] Guo, J., Yu, C., Li, H., Liu, F., Feng, R., Wang, H., Meng, Y., Li, Z., Ju, G., Wang, J., Impaired neural stem/progenitor cell proliferation in streptozotocin-induced and spontaneous diabetic mice. Neurosci. Res. 68 (2010), 329–336.
46. [46] Li, J., Tang, Y., Cai, D., IKKbeta/NF-kappaB disrupts adult hypothalamic neural stem cells to mediate a neurodegenerative mechanism of dietary obesity and pre-diabetes. Nat. Cell Biol. 14 (2012), 999–1012.
47. [47] Qin, L., Bouchard, R., Pugazhenthi, S., Regulation of cAMP response element binding protein during neuroglial interactions. J. Neurochem., 2015.
48. [48] Goh, S.Y., Cooper, M.E., Clinical review: the role of advanced glycation end products in progression and complications of diabetes. J. Clin. Endocrinol. Metab. 93 (2008), 1143–1152.
49. [49] Srikanth, V., Maczurek, A., Phan, T., Steele, M., Westcott, B., Juskiw, D., Munch, G., Advanced glycation endproducts and their receptor RAGE in Alzheimer's disease. Neurobiol. Aging 32 (2011), 763–777.
50. [50] Toth, C., Martinez, J., Zochodne, D.W., RAGE, diabetes, and the nervous system. Curr. Mol. Med. 7 (2007), 766–776.
51. [51] Guglielmotto, M., Aragno, M., Tamagno, E., Vercellinatto, I., Visentin, S., Medana, C., Catalano, M.G., Smith, M.A., Perry, G., Danni, O., Boccuzzi, G., Tabaton, M., AGEs/RAGE complex upregulates BACE1 via NF-kappaB pathway activation. Neurobiol. Aging 33:196 (2012), e113–e127.
52. [52] Kojro, E., Postina, R., Regulated proteolysis of RAGE and AbetaPP as possible link between type 2 diabetes mellitus and Alzheimer's disease. J. Alzheimers Dis. 16 (2009), 865–878.
53. [53] Liu, L.P., Hong, H., Liao, J.M., Wang, T.S., Wu, J., Chen, S.S., Li, Y.Q., Long, Y., Xia, Y.Z., Upregulation of RAGE at the blood–brain barrier in streptozotocin-induced diabetic mice. Synapse 63 (2009), 636–642.
54. [54] Cai, W., Uribarri, J., Zhu, L., Chen, X., Swamy, S., Zhao, Z., Grosjean, F., Simonaro, C., Kuchel, G.A., Schnaider-Beeri, M., Woodward, M., Striker, G.E., Vlassara, H., Oral glycotoxins are a modifiable cause of dementia and the metabolic syndrome in mice and humans. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), 4940–4945.
55. [55] Beeri, M.S., Moshier, E., Schmeidler, J., Godbold, J., Uribarri, J., Reddy, S., Sano, M., Grossman, H.T., Cai, W., Vlassara, H., Silverman, J.M., Serum concentration of an inflammatory glycotoxin, methylglyoxal, is associated with increased cognitive decline in elderly individuals. Mech. Ageing Dev. 132 (2011), 583–587.
56. [56] Byun, K., Bayarsaikhan, E., Kim, D., Kim, C.Y., Mook-Jung, I., Paek, S.H., Kim, S.U., Yamamoto, T., Won, M.H., Song, B.J., Park, Y.M., Lee, B., Induction of neuronal death by microglial AGE-albumin: implications for Alzheimer's disease. PLoS One, 7, 2012, e37917.
57. [57] Yan, S.D., Chen, X., Fu, J., Chen, M., Zhu, H., Roher, A., Slattery, T., Zhao, L., Nagashima, M., Morser, J., Migheli, A., Nawroth, P., Stern, D., Schmidt, A.M., RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 382 (1996), 685–691.
58. [58] Lue, L.F., Walker, D.G., Brachova, L., Beach, T.G., Rogers, J., Schmidt, A.M., Stern, D.M., Yan, S.D., Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer's disease: identification of a cellular activation mechanism. Exp. Neurol. 171 (2001), 29–45.
59. [59] Choi, B.R., Cho, W.H., Kim, J., Lee, H.J., Chung, C., Jeon, W.K., Han, J.S., Increased expression of the receptor for advanced glycation end products in neurons and astrocytes in a triple transgenic mouse model of Alzheimer's disease. Exp. Mol. Med., 46, 2014, e75.
60. [60] Sasaki, N., Toki, S., Chowei, H., Saito, T., Nakano, N., Hayashi, Y., Takeuchi, M., Makita, Z., Immunohistochemical distribution of the receptor for advanced glycation end products in neurons and astrocytes in Alzheimer's disease. Brain Res. 888 (2001), 256–262.
61. [61] Miller, M.C., Tavares, R., Johanson, C.E., Hovanesian, V., Donahue, J.E., Gonzalez, L., Silverberg, G.D., Stopa, E.G., Hippocampal RAGE immunoreactivity in early and advanced Alzheimer's disease. Brain Res. 1230 (2008), 273–280.
62. [62] Wang, X., Yu, S., Hu, J.P., Wang, C.Y., Wang, Y., Liu, H.X., Liu, Y.L., Streptozotocin-induced diabetes increases amyloid plaque deposition in AD transgenic mice through modulating AGEs/RAGE/NF-kappaB pathway. Int. J. Neurosci. 124 (2014), 601–608.
63. [63] Fang, F., Lue, L.F., Yan, S., Xu, H., Luddy, J.S., Chen, D., Walker, D.G., Stern, D.M., Schmidt, A.M., Chen, J.X., Yan, S.S., RAGE-dependent signaling in microglia contributes to neuroinflammation, Abeta accumulation, and impaired learning/memory in a mouse model of Alzheimer's disease. FASEB J. 24 (2010), 1043–1055.
64. [64] Arancio, O., Zhang, H.P., Chen, X., Lin, C., Trinchese, F., Puzzo, D., Liu, S., Hegde, A., Yan, S.F., Stern, A., Luddy, J.S., Lue, L.F., Walker, D.G., Roher, A., Buttini, M., Mucke, L., Li, W., Schmidt, A.M., Kindy, M., Hyslop, P.A., Stern, D.M., Yan, S.S.D., RAGE potentiates Abeta-induced perturbation of neuronal function in transgenic mice. EMBO J. 23 (2004), 4096–4105.
65. [65] Deane, R., Singh, I., Sagare, A.P., Bell, R.D., Ross, N.T., LaRue, B., Love, R., Perry, S., Paquette, N., Deane, R.J., Thiyagarajan, M., Zarcone, T., Fritz, G., Friedman, A.E., Miller, B.L., Zlokovic, B.V., A multimodal RAGE-specific inhibitor reduces amyloid beta-mediated brain disorder in a mouse model of Alzheimer disease. J. Clin. Invest. 122 (2012), 1377–1392.
66. [66] Galasko, D., Bell, J., Mancuso, J.Y., Kupiec, J.W., Sabbagh, M.N., van Dyck, C., Thomas, R.G., Aisen, P.S., Clinical trial of an inhibitor of RAGE-Abeta interactions in Alzheimer disease. Neurology 82 (2014), 1536–1542.
67. [67] Walker, D., Lue, L.F., Paul, G., Patel, A., Sabbagh, M.N., Receptor for advanced glycation endproduct modulators: a new therapeutic target in Alzheimer's disease. Expert Opin. Investig. Drugs 24 (2015), 393–399.
68. [68] Selvin, E., Halushka, M.K., Rawlings, A.M., Hoogeveen, R.C., Ballantyne, C.M., Coresh, J., Astor, B.C., sRAGE and risk of diabetes, cardiovascular disease, and death. Diabetes 62 (2013), 2116–2121.
69. [69] Liang, F., Jia, J., Wang, S., Qin, W., Liu, G., Decreased plasma levels of soluble low density lipoprotein receptor-related protein-1 (sLRP) and the soluble form of the receptor for advanced glycation end products (sRAGE) in the clinical diagnosis of Alzheimer's disease. J. Clin. Neurosci. 20 (2013), 357–361.
70. [70] Cai, W., Ramdas, M., Zhu, L., Chen, X., Striker, G.E., Vlassara, H., Oral advanced glycation endproducts (AGEs) promote insulin resistance and diabetes by depleting the antioxidant defenses AGE receptor-1 and sirtuin 1. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), 15888–15893.
71. [71] Poulsen, M.W., Hedegaard, R.V., Andersen, J.M., de Courten, B., Bugel, S., Nielsen, J., Skibsted, L.H., Dragsted, L.O., Advanced glycation endproducts in food and their effects on health. Food Chem. Toxicol. 60 (2013), 10–37.
72. [72] West, R.K., Moshier, E., Lubitz, I., Schmeidler, J., Godbold, J., Cai, W., Uribarri, J., Vlassara, H., Silverman, J.M., Beeri, M.S., Dietary advanced glycation end products are associated with decline in memory in young elderly. Mech. Ageing Dev. 140 (2014), 10–12.
73. [73] Carvalho, C., Cardoso, S., Correia, S.C., Santos, R.X., Santos, M.S., Baldeiras, I., Oliveira, C.R., Moreira, P.I., Metabolic alterations induced by sucrose intake and Alzheimer's disease promote similar brain mitochondrial abnormalities. Diabetes 61 (2012), 1234–1242.
74. [74] Gurung, P., Lukens, J.R., Kanneganti, T.D., Mitochondria: diversity in the regulation of the NLRP3 inflammasome. Trends Mol. Med. 21 (2015), 193–201.
75. [75] Sorbara, M.T., Girardin, S.E., Mitochondrial ROS fuel the inflammasome. Cell Res. 21 (2011), 558–560.
76. [76] West, A.P., Khoury-Hanold, W., Staron, M., Tal, M.C., Pineda, C.M., Lang, S.M., Bestwick, M., Duguay, B.A., Raimundo, N., MacDuff, D.A., Kaech, S.M., Smiley, J.R., Means, R.E., Iwasaki, A., Shadel, G.S., Mitochondrial DNA stress primes the antiviral innate immune response. Nature, 2015.
77. [77] Lamkanfi, M., Dixit, V.M., Mechanisms and functions of inflammasomes. Cell 157 (2014), 1013–1022.
78. [78] Laudisi, F., Spreafico, R., Evrard, M., Hughes, T.R., Mandriani, B., Kandasamy, M., Morgan, B.P., Sivasankar, B., Mortellaro, A., Cutting edge: the NLRP3 inflammasome links complement-mediated inflammation and IL-1beta release. J. Immunol. 191 (2013), 1006–1010.
79. [79] Kaushal, V., Dye, R., Pakavathkumar, P., Foveau, B., Flores, J., Hyman, B., Ghetti, B., Koller, B.H., LeBlanc, A.C., Neuronal NLRP1 inflammasome activation of Caspase-1 coordinately regulates inflammatory interleukin-1-beta production and axonal degeneration-associated Caspase-6 activation. Cell Death Differ., 2015.
80. [80] Shimada, K., Crother, T.R., Karlin, J., Dagvadorj, J., Chiba, N., Chen, S., Ramanujan, V.K., Wolf, A.J., Vergnes, L., Ojcius, D.M., Rentsendorj, A., Vargas, M., Guerrero, C., Wang, Y., Fitzgerald, K.A., Underhill, D.M., Town, T., Arditi, M., Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis. Immunity 36 (2012), 401–414.
81. [81] Motori, E., Puyal, J., Toni, N., Ghanem, A., Angeloni, C., Malaguti, M., Cantelli-Forti, G., Berninger, B., Conzelmann, K.K., Gotz, M., Winklhofer, K.F., Hrelia, S., Bergami, M., Inflammation-induced alteration of astrocyte mitochondrial dynamics requires autophagy for mitochondrial network maintenance. Cell Metab. 18 (2013), 844–859.
82. [82] Poitout, V., Robertson, R.P., Glucolipotoxicity: fuel excess and beta-cell dysfunction. Endocr. Rev. 29 (2008), 351–366.
83. [83] Wen, H., Gris, D., Lei, Y., Jha, S., Zhang, L., Huang, M.T., Brickey, W.J., Ting, J.P., Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nat. Immunol. 12 (2011), 408–415.
84. [84] Burm, S.M., Zuiderwijk-Sick, E.A., Jong, A.E.T., van der Putten, C., Veth, J., Kondova, I., Bajramovic, J.J., Inflammasome-induced IL-1beta secretion in microglia is characterized by delayed kinetics and is only partially dependent on inflammatory caspases. J. Neurosci. 35 (2015), 678–687.
85. [85] Cai, D., One step from prediabetes to diabetes: hypothalamic inflammation?. Endocrinology 153 (2012), 1010–1013.
86. [86] Rubartelli, A., DAMP-mediated activation of NLRP3-inflammasome in brain sterile inflammation: the fine line between healing and neurodegeneration. Front. Immunol., 5, 2014, 99.
87. [87] Jabaut, J., Ather, J.L., Taracanova, A., Poynter, M.E., Ckless, K., Mitochondria-targeted drugs enhance Nlrp3 inflammasome-dependent IL-1beta secretion in association with alterations in cellular redox and energy status. Free Radic. Biol. Med. 60 (2013), 233–245.
88. [88] Sokolowski, J.D., Chabanon-Hicks, C.N., Han, C.Z., Heffron, D.S., Mandell, J.W., Fractalkine is a “find-me” signal released by neurons undergoing ethanol-induced apoptosis. Front. Cell. Neurosci., 8, 2014, 360.
89. [89] Min, S.W., Sohn, P.D., Cho, S.H., Swanson, R.A., Gan, L., Sirtuins in neurodegenerative diseases: an update on potential mechanisms. Front. Aging Neurosci., 5, 2013, 53.
90. [90] Ng, F., Wijaya, L., Tang, B.L., SIRT1 in the brain-connections with aging-associated disorders and lifespan. Front. Cell. Neurosci., 9, 2015, 64.
91. [91] Gan, L., Mucke, L., Paths of convergence: sirtuins in aging and neurodegeneration. Neuron 58 (2008), 10–14.
92. [92] Chen, J., Zhou, Y., Mueller-Steiner, S., Chen, L.F., Kwon, H., Yi, S., Mucke, L., Gan, L., SIRT1 protects against microglia-dependent amyloid-beta toxicity through inhibiting NF-kappaB signaling. J. Biol. Chem. 280 (2005), 40364–40374.
93. [93] Yoshizaki, T., Milne, J.C., Imamura, T., Schenk, S., Sonoda, N., Babendure, J.L., Lu, J.C., Smith, J.J., Jirousek, M.R., Olefsky, J.M., SIRT1 exerts anti-inflammatory effects and improves insulin sensitivity in adipocytes. Mol. Cell. Biol. 29 (2009), 1363–1374.
94. [94] Glass, C.K., Saijo, K., Winner, B., Marchetto, M.C., Gage, F.H., Mechanisms underlying inflammation in neurodegeneration. Cell 140 (2010), 918–934.
95. [95] Wright, A.L., Zinn, R., Hohensinn, B., Konen, L.M., Beynon, S.B., Tan, R.P., Clark, I.A., Abdipranoto, A., Vissel, B., Neuroinflammation and neuronal loss precede Abeta plaque deposition in the hAPP-J20 mouse model of Alzheimer's disease. PLoS One, 8, 2013, e59586.
96. [96] Hanzel, C.E., Pichet-Binette, A., Pimentel, L.S., Iulita, M.F., Allard, S., Ducatenzeiler, A., Do Carmo, S., Cuello, A.C., Neuronal driven pre-plaque inflammation in a transgenic rat model of Alzheimer's disease. Neurobiol. Aging 35 (2014), 2249–2262.
97. [97] Di Filippo, M., Chiasserini, D., Gardoni, F., Viviani, B., Tozzi, A., Giampa, C., Costa, C., Tantucci, M., Zianni, E., Boraso, M., Siliquini, S., de Iure, A., Ghiglieri, V., Colcelli, E., Baker, D., Sarchielli, P., Fusco, F.R., Di Luca, M., Calabresi, P., Effects of central and peripheral inflammation on hippocampal synaptic plasticity. Neurobiol. Dis. 52 (2013), 229–236.
98. [98] Franceschi, C., Inflammaging as a major characteristic of old people: can it be prevented or cured?. Nutr. Rev. 65 (2007), S173–S176.
99. [99] Shoelson, S.E., Lee, J., Goldfine, A.B., Inflammation and insulin resistance. J. Clin. Invest. 116 (2006), 1793–1801.
100. [100] Skelly, D.T., Hennessy, E., Dansereau, M.A., Cunningham, C., A systematic analysis of the peripheral and CNS effects of systemic LPS, IL-1beta, [corrected] TNF-alpha and IL-6 challenges in C57BL/6 mice. PLoS One, 8, 2013, e69123.
101. [101] Krstic, D., Madhusudan, A., Doehner, J., Vogel, P., Notter, T., Imhof, C., Manalastas, A., Hilfiker, M., Pfister, S., Schwerdel, C., Riether, C., Meyer, U., Knuesel, I., Systemic immune challenges trigger and drive Alzheimer-like neuropathology in mice. J. Neuroinflammation, 9, 2012, 151.
102. [102] Swardfager, W., Lanctot, K., Rothenburg, L., Wong, A., Cappell, J., Herrmann, N., A meta-analysis of cytokines in Alzheimer's disease. Biol. Psychiatry 68 (2010), 930–941.
103. [103] Zhang, R., Miller, R.G., Madison, C., Jin, X., Honrada, R., Harris, W., Katz, J., Forshew, D.A., McGrath, M.S., Systemic immune system alterations in early stages of Alzheimer's disease. J. Neuroimmunol. 256 (2013), 38–42.
104. [104] Bermejo, P., Martin-Aragon, S., Benedi, J., Susin, C., Felici, E., Gil, P., Ribera, J.M., Villar, A.M., Differences of peripheral inflammatory markers between mild cognitive impairment and Alzheimer's disease. Immunol. Lett. 117 (2008), 198–202.
105. [105] van Himbergen, T.M., Beiser, A.S., Ai, M., Seshadri, S., Otokozawa, S., Au, R., Thongtang, N., Wolf, P.A., Schaefer, E.J., Biomarkers for insulin resistance and inflammation and the risk for all-cause dementia and Alzheimer disease: results from the Framingham Heart Study. Arch. Neurol. 69 (2012), 594–600.
106. [106] Koyama, A., O'Brien, J., Weuve, J., Blacker, D., Metti, A.L., Yaffe, K., The role of peripheral inflammatory markers in dementia and Alzheimer's disease: a meta-analysis. J. Gerontol. Ser. A Biol. Sci. Med. Sci. 68 (2013), 433–440.
107. [107] Tan, Z.S., Beiser, A.S., Vasan, R.S., Roubenoff, R., Dinarello, C.A., Harris, T.B., Benjamin, E.J., Au, R., Kiel, D.P., Wolf, P.A., Seshadri, S., Inflammatory markers and the risk of Alzheimer disease: the Framingham Study. Neurology 68 (2007), 1902–1908.
108. [108] Magaki, S., Mueller, C., Dickson, C., Kirsch, W., Increased production of inflammatory cytokines in mild cognitive impairment. Exp. Gerontol. 42 (2007), 233–240.
109. [109] Peng, L., Xu, L., Ouyang, W., Role of peripheral inflammatory markers in postoperative cognitive dysfunction (POCD): a meta-analysis. PLoS One, 8, 2013, e79624.
110. [110] Banks, W.A., Kastin, A.J., Blood to brain transport of interleukin links the immune and central nervous systems. Life Sci. 48 (1991), PL117–PL121.
111. [111] Banks, W.A., Kastin, A.J., Broadwell, R.D., Passage of cytokines across the blood–brain barrier. Neuroimmunomodulation 2 (1995), 241–248.
112. [112] Gutierrez, E.G., Banks, W.A., Kastin, A.J., Murine tumor necrosis factor alpha is transported from blood to brain in the mouse. J. Neuroimmunol. 47 (1993), 169–176.
113. [113] Dilger, R.N., Johnson, R.W., Aging, microglial cell priming, and the discordant central inflammatory response to signals from the peripheral immune system. J. Leukoc. Biol. 84 (2008), 932–939.
114. [114] Thomson, C.A., McColl, A., Cavanagh, J., Graham, G.J., Peripheral inflammation is associated with remote global gene expression changes in the brain. J. Neuroinflammation, 11, 2014, 73.
115. [115] Haseloff, R.F., Dithmer, S., Winkler, L., Wolburg, H., Blasig, I.E., Transmembrane proteins of the tight junctions at the blood–brain barrier: structural and functional aspects. Semin. Cell Dev. Biol. 38 (2015), 16–25.
116. [116] Montagne, A., Barnes, S.R., Sweeney, M.D., Halliday, M.R., Sagare, A.P., Zhao, Z., Toga, A.W., Jacobs, R.E., Liu, C.Y., Amezcua, L., Harrington, M.G., Chui, H.C., Law, M., Zlokovic, B.V., Blood–brain barrier breakdown in the aging human hippocampus. Neuron 85 (2015), 296–302.
117. [117] Freeman, L.R., Granholm, A.C., Vascular changes in rat hippocampus following a high saturated fat and cholesterol diet. J. Cereb. Blood Flow Metab. 32 (2012), 643–653.
118. [118] Davidson, T.L., Monnot, A., Neal, A.U., Martin, A.A., Horton, J.J., Zheng, W., The effects of a high-energy diet on hippocampal-dependent discrimination performance and blood–brain barrier integrity differ for diet-induced obese and diet-resistant rats. Physiol. Behav. 107 (2012), 26–33.
119. [119] Tucsek, Z., Toth, P., Sosnowska, D., Gautam, T., Mitschelen, M., Koller, A., Szalai, G., Sonntag, W.E., Ungvari, Z., Csiszar, A., Obesity in aging exacerbates blood–brain barrier disruption, neuroinflammation, and oxidative stress in the mouse hippocampus: effects on expression of genes involved in beta-amyloid generation and Alzheimer's disease. J. Gerontol. Ser. A Biol. Sci. Med. Sci. 69 (2014), 1212–1226.
120. [120] Pallebage-Gamarallage, M., Lam, V., Takechi, R., Galloway, S., Clark, K., Mamo, J., Restoration of dietary-fat induced blood–brain barrier dysfunction by anti-inflammatory lipid-modulating agents. Lipids Health Dis., 11, 2012, 117.
121. [121] Mortuza, R., Chen, S., Feng, B., Sen, S., Chakrabarti, S., High glucose induced alteration of SIRTs in endothelial cells causes rapid aging in a p300 and FOXO regulated pathway. PLoS One, 8, 2013, e54514.
122. [122] Allen, C.L., Bayraktutan, U., Antioxidants attenuate hyperglycaemia-mediated brain endothelial cell dysfunction and blood–brain barrier hyperpermeability. Diabetes Obes. Metab. 11 (2009), 480–490.
123. [123] Navaratna, D., Fan, X., Leung, W., Lok, J., Guo, S., Xing, C., Wang, X., Lo, E.H., Cerebrovascular degradation of TRKB by MMP9 in the diabetic brain. J. Clin. Invest. 123 (2013), 3373–3377.
124. [124] Liu, G., Cao, M., Xu, Y., Li, Y., SIRT3 protects endothelial cells from high glucose-induced cytotoxicity. Int. J. Clin. Exp. Pathol. 8 (2015), 353–360.
125. [125] Ouyang, S., Hsuchou, H., Kastin, A.J., Wang, Y., Yu, C., Pan, W., Diet-induced obesity suppresses expression of many proteins at the blood–brain barrier. J. Cereb. Blood Flow Metab. 34 (2014), 43–51.
126. [126] Ott, A., Stolk, R., Harskamp, F.V., Pols, H., Hoffman, A., Breteler, M., Diabetes mellitus and the risk of dementia. The Rotterdam study. Neurology, 53(1999), 1937-1942.
127. [127] Huang, C.C., Chung, C.M., Leu, H.B., Lin, L.Y., Chiu, C.C., Hsu, C.Y., Chiang, C.H., Huang, P.H., Chen, T.J., Lin, S.J., Chen, J.W., Chan, W.L., Diabetes mellitus and the risk of Alzheimer's disease: a nationwide population-based study. PLoS One, 9, 2014, e87095.
128. [128] Ho, A.J., Raji, C.A., Becker, J.T., Lopez, O.L., Kuller, L.H., Hua, X., Lee, S., Hibar, D., Dinov, I.D., Stein, J.L., Jack, C.R. Jr., Weiner, M.W., Toga, A.W., Thompson, P.M., Obesity is linked with lower brain volume in 700 AD and MCI patients. Neurobiol. Aging 31 (2010), 1326–1339.
129. [129] Profenno, L.A., Porsteinsson, A.P., Faraone, S.V., Meta-analysis of Alzheimer's disease risk with obesity, diabetes, and related disorders. Biol. Psychiatry 67 (2010), 505–512.
130. [130] Wang, K.C., Woung, L.C., Tsai, M.T., Liu, C.C., Su, Y.H., Li, C.Y., Risk of Alzheimer's disease in relation to diabetes: a population-based cohort study. Neuroepidemiology 38 (2012), 237–244.
131. [131] Chuang, Y.F., An, Y., Bilgel, M., Wong, D.F., Troncoso, J.C., O'Brien, R.J., Breitner, J.C., Ferruci, L., Resnick, S.M., Thambisetty, M., Midlife adiposity predicts earlier onset of Alzheimer's dementia, neuropathology and presymptomatic cerebral amyloid accumulation. Mol. Psychiatry, 2015.
132. [132] Ho, L., Qin, W., Pompl, P.N., Xiang, Z., Wang, J., Zhao, Z., Peng, Y., Cambareri, G., Rocher, A., Mobbs, C.V., Hof, P.R., Pasinetti, G.M., Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. FASEB J. 18 (2004), 902–904.
133. [133] Jolivalt, C.G., Hurford, R., Lee, C.A., Dumaop, W., Rockenstein, E., Masliah, E., Type 1 diabetes exaggerates features of Alzheimer's disease in APP transgenic mice. Exp. Neurol. 223 (2010), 422–431.
134. [134] Takeda, S., Sato, N., Uchio-Yamada, K., Sawada, K., Kunieda, T., Takeuchi, D., Kurinami, H., Shinohara, M., Rakugi, H., Morishita, R., Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and Abeta deposition in an Alzheimer mouse model with diabetes. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 7036–7041.
135. [135] Kohjima, M., Sun, Y., Chan, L., Increased food intake leads to obesity and insulin resistance in the tg2576 Alzheimer's disease mouse model. Endocrinology 151 (2010), 1532–1540.
136. [136] Fu, W., Patel, A., Jhamandas, J.H., Amylin receptor: a common pathophysiological target in Alzheimer's disease and diabetes mellitus. Front. Aging Neurosci., 5, 2013, 42.
137. [137] Ioacara, S., Guja, C., Ionescu-Tirgoviste, C., Fica, S., Sabau, S., Radu, S., Micu, A., Tiu, C., Improvements in life expectancy in adult type 2 diabetes patients in the last six decades. Diabetes Res. Clin. Pract. 92 (2011), 400–404.
138. [138] Han, W., Li, C., Linking type 2 diabetes and Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 6557–6558.